2 citations
,
February 2018 in “InTech eBooks” TNF-alpha inhibitors can cause various immune-related skin issues.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
Baricitinib may effectively treat oral lichen planus.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
August 2022 in “Revista de la Universidad Industrial de Santander/Salud UIS” Stress-related hair loss was reversed with a special medication.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
1 citations
,
July 2012 in “Nasza Dermatologia Online” IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.
September 2024 in “South Eastern European Journal of Public Health” Alopecia areata patients have higher IgE and IL-13 levels, suggesting immune involvement.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
5 citations
,
April 2024 in “Journal of the Pakistan Medical Association” Interleukin-6 may play a role in causing alopecia areata.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
1 citations
,
September 2023 in “Rheumatology advances in practice” A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
February 2024 in “Trends in Sciences” Store Tectona grandis leaf extracts in slightly acidic, light-protected conditions for best stability.
June 2023 in “Benha Journal of Applied Sciences” Targeting IL-17 could help treat pattern hair loss.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
15 citations
,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
9 citations
,
August 2000 in “Journal of Periodontal Research” Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.